GSK

News

Gilead's already dominant position in HIV PrEP could be extended if the FDA approves a new twice-yearly injectable product later this year.

News

GSK joins arch-rival Pfizer in the market for five-in-one meningococcal vaccines with FDA approval for Penmenvy, a top launch prospect for 2025.

News

Despite a steep fall-off in sales of RSV vaccine Arexvy last year, GSK has raised its long-term sales forecast to £40 billion in 2031.

News

Regulators have started reviews of GSK's depemokimab, aiming to become the first drug for asthma that can be dosed twice a year.

News

A GSK alliance with Oxford University aims to identify precancerous changes in cells that could form the basis of preventive vaccines.

News

Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU.